Praxis (Drug Discovery) Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 109

Employees

  • Stock Symbol
  • PRAX

Stock Symbol

  • Share Price
  • $40.18
  • (As of Tuesday Closing)

Praxis (Drug Discovery) General Information

Description

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.

Contact Information

Formerly Known As
EpiPM Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 99 High Street
  • 30th Floor
  • Boston, MA 02110
  • United States
+1 (617) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Praxis (Drug Discovery) Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$40.18 $41.81 $11.85 - $54.22 $524M 13M 146K -$29.85

Praxis (Drug Discovery) Financials Summary

In Thousands,
USD
TTM 30-Sep-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 98,514 (7,865) 573,702 2,223,570
Revenue 1,932 0 0 0
EBITDA (137,146) (213,610) (166,879) (61,778)
Net Income (137,572) (214,029) (167,061) (61,820)
Total Assets 106,725 115,128 292,747 303,177
Total Debt 2,756 3,500 4,311 763
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Praxis (Drug Discovery) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Praxis (Drug Discovery)‘s full profile, request access.

Request a free trial

Praxis (Drug Discovery) Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Praxis (Drug Discovery)‘s full profile, request access.

Request a free trial

Praxis (Drug Discovery) Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic
Drug Discovery
Boston, MA
109 As of 2022
00000
00000000 00000

0000 0

ctetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore mag
0000 000000000
Cambridge, MA
000 As of 0000
00.000
000000000 00.000

00000

empor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis
0000000000000
Burnaby, Canada
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Praxis (Drug Discovery) Competitors (7)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
SAGE Therapeutics Formerly VC-backed Cambridge, MA 000 00.000 000000000 00.000
Xenon Pharmaceuticals Formerly VC-backed Burnaby, Canada 000 00000 00000000 00000
Aquinnah Venture Capital-Backed Cambridge, MA 00 0000 0000000000 0000
Quince Therapeutics Formerly VC-backed South San Francisco, CA 00 00000 000000&0
Stoke Therapeutics Formerly VC-backed Bedford, MA 000 00000 00000000 00000
You’re viewing 5 of 7 competitors. Get the full list »

Praxis (Drug Discovery) Patents

Praxis (Drug Discovery) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220289789-A1 Hemi-citrate salts of gaba-a positive allosteric modulator and crystalline form thereof Active 18-Feb-2021 0000000000 0
US-11697669-B2 Hemi-citrate salts of gaba-a positive allosteric modulator and crystalline form thereof Active 18-Feb-2021 0000000000 0
EP-4294819-A1 Hemi-citrate salts of gaba-a positive allosteric modulator and crystalline form thereof Pending 18-Feb-2021 000000000
EP-4267133-A2 Kcnt1 inhibitors and methods of use Pending 22-Dec-2020 0000000000
US-20240043415-A1 Kcnt1 inhibitors and methods of use Pending 22-Dec-2020 C07D413/12
To view Praxis (Drug Discovery)’s complete patent history, request access »

Praxis (Drug Discovery) Executive Team (13)

Name Title Board Seat Contact Info
Marcio Souza Chief Executive Officer, President & Director
Tim Kelly Chief Financial Officer
Lauren Mastrocola Chief Accounting Officer, Accounting
Kelly McCue Chief People Officer
Steven Petrou Ph.D Co-Founder & Chief Scientific Officer
You’re viewing 5 of 13 executive team members. Get the full list »

Praxis (Drug Discovery) Board Members (13)

Name Representing Role Since
Dean Mitchell Self Chairman & Board Member 000 0000
Geoff Lewis Self Board Member 000 0000
Gregory Norden Self Board Member 000 0000
Jeffrey Chodakewitz MD Praxis (Drug Discovery) Board Member 000 0000
Marcio Souza Praxis (Drug Discovery) Chief Executive Officer, President & Director 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Praxis (Drug Discovery) Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Praxis (Drug Discovery) Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Praxis (Drug Discovery)‘s full profile, request access.

Request a free trial

Praxis (Drug Discovery) ESG

Risk Overview

Risk Rating

Updated October, 01, 2023

34.63 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,708

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 884

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 418

Rank

00.00

Percentile

To view Praxis (Drug Discovery)’s complete esg history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »